

James B Dale

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2327756/publications.pdf>

Version: 2024-02-01

126
papers

7,444
citations

46918

47
h-index

62479

80
g-index

130
all docs

130
docs citations

130
times ranked

3230
citing authors

#	ARTICLE	IF	CITATIONS
1	Cross-reactive immunogenicity of group A streptococcal vaccines designed using a recurrent neural network to identify conserved M protein linear epitopes. <i>Vaccine</i> , 2021, 39, 1773-1779.	1.7	4
2	A controlled human infection model of <i>Streptococcus pyogenes</i> pharyngitis (CHIVAS-M75): an observational, dose-finding study. <i>Lancet Microbe</i> , The, 2021, 2, e291-e299.	3.4	29
3	Utility of Human Immune Responses to GAS Antigens as a Diagnostic Indicator for ARF: A Systematic Review. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 691646.	1.1	2
4	Design of Broadly Cross-Reactive M Protein-Based Group A Streptococcal Vaccines. <i>Journal of Immunology</i> , 2021, 207, 1138-1149.	0.4	9
5	Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study. <i>Vaccine</i> , 2020, 38, 1384-1392.	1.7	53
6	Systematic Review and Meta-analysis of the Prevalence of Group A Streptococcal Clusters in Africa To Inform Vaccine Development. <i>MSphere</i> , 2020, 5, .	1.3	11
7	The American Heart Association's Call to Action for Reducing the Global Burden of Rheumatic Heart Disease: A Policy Statement From the American Heart Association. <i>Circulation</i> , 2020, 142, e358-e368.	1.6	30
8	Update on group A streptococcal vaccine development. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 244-250.	1.3	56
9	Immunotherapy targeting the <i>Streptococcus pyogenes</i> M protein or streptolysin O to treat or prevent influenza A superinfection. <i>PLoS ONE</i> , 2020, 15, e0235139.	1.1	3
10	Prevalence of group A β -hemolytic streptococcal throat carriage and prospective pilot surveillance of streptococcal sore throat in Ugandan school children. <i>International Journal of Infectious Diseases</i> , 2020, 93, 245-251.	1.5	21
11	Structure-based group A streptococcal vaccine design: Helical wheel homology predicts antibody cross-reactivity among streptococcal M protein-derived peptides. <i>Journal of Biological Chemistry</i> , 2020, 295, 3826-3836.	1.6	8
12	Group A Streptococcal Virulence: New Lessons. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2019, 8, 160-161.	0.6	2
13	Controlled human infection for vaccination against <i>Streptococcus pyogenes</i> (CHIVAS): Establishing a group A <i>Streptococcus</i> pharyngitis human infection study. <i>Vaccine</i> , 2019, 37, 3485-3494.	1.7	31
14	Molecular Epidemiology of Noninvasive and Invasive Group A Streptococcal Infections in Cape Town. <i>MSphere</i> , 2019, 4, .	1.3	7
15	Development of an Opsonophagocytic Killing Assay Using HL-60 Cells for Detection of Functional Antibodies against <i>Streptococcus pyogenes</i> . <i>MSphere</i> , 2018, 3, .	1.3	16
16	Clinical and microbiological response of mice to intranasal inoculation with <i>Lactococcus lactis</i> expressing Group A <i>Streptococcus</i> antigens, to be used as an anti-streptococcal vaccine. <i>Microbiology and Immunology</i> , 2018, 62, 711-719.	0.7	5
17	Protective immunity induced by an intranasal multivalent vaccine comprising 10 <i>Lactococcus lactis</i> strains expressing highly prevalent M protein antigens derived from Group A <i>Streptococcus</i> . <i>Microbiology and Immunology</i> , 2018, 62, 395-404.	0.7	6
18	Blocking Neuronal Signaling to Immune Cells Treats Streptococcal Invasive Infection. <i>Cell</i> , 2018, 173, 1083-1097.e22.	13.5	265

#	ARTICLE	IF	CITATIONS
19	Prospective Longitudinal Analysis of Immune Responses in Pediatric Subjects After Pharyngeal Acquisition of Group A Streptococci. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, 187-196.	0.6	47
20	The Cape Town Clinical Decision Rule for Streptococcal Pharyngitis in Children. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 250-255.	1.1	16
21	Structure-based design of broadly protective group a streptococcal M protein-based vaccines. <i>Vaccine</i> , 2017, 35, 19-26.	1.7	41
22	Immune Cross-Opsonization Withinemm Clusters Following Group A Streptococcus Skin Infection: Broadening the Scope of Type-Specific Immunity. <i>Clinical Infectious Diseases</i> , 2017, 65, 1523-1531.	2.9	45
23	Trivalent M-related protein as a component of next generation group A streptococcal vaccines. <i>Clinical and Experimental Vaccine Research</i> , 2017, 6, 45.	1.1	18
24	Rationale and design of the African group A streptococcal infection registry: the AFROStrepstudy. <i>BMJ Open</i> , 2016, 6, e010248.	0.8	13
25	One More Disguise in the Stealth Behavior of <i>Streptococcus pyogenes</i> . <i>MBio</i> , 2016, 7, .	1.8	8
26	Status of research and development of vaccines for <i>Streptococcus pyogenes</i> . <i>Vaccine</i> , 2016, 34, 2953-2958.	1.7	113
27	Streptococcal Pharyngitis in Schoolchildren in Bamako, Mali. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 463-468.	1.1	19
28	Protective Immunogenicity of Group A Streptococcal M-Related Proteins. <i>Vaccine Journal</i> , 2015, 22, 344-350.	3.2	18
29	Added Value of the emm-Cluster Typing System to Analyze Group A Streptococcus Epidemiology in High-Income Settings. <i>Clinical Infectious Diseases</i> , 2014, 59, 1651-1652.	2.9	40
30	A Systematic and Functional Classification of <i>Streptococcus pyogenes</i> That Serves as a New Tool for Molecular Typing and Vaccine Development. <i>Journal of Infectious Diseases</i> , 2014, 210, 1325-1338.	1.9	257
31	Group A Streptococcus Expresses a Trio of Surface Proteins Containing Protective Epitopes. <i>Vaccine Journal</i> , 2014, 21, 1421-1425.	3.2	6
32	Vaccination against the M protein of <i>Streptococcus pyogenes</i> prevents death after influenza virus:S. <i>pyogenes</i> super-infection. <i>Vaccine</i> , 2014, 32, 5241-5249.	1.7	20
33	A Novel Live Vector Group A StreptococcalemmType 9 Vaccine Delivered Intranasally Protects Mice against Challenge Infection withemmType 9 Group A Streptococci. <i>Vaccine Journal</i> , 2014, 21, 1343-1349.	3.2	8
34	Group A Streptococcal emm Type Prevalence Among Symptomatic Children in Cape Town and Potential Vaccine Coverage. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 208-210.	1.1	33
35	Potential coverage of a multivalent M protein-based group A streptococcal vaccine. <i>Vaccine</i> , 2013, 31, 1576-1581.	1.7	82
36	Group A streptococcal vaccines: Paving a path for accelerated development. <i>Vaccine</i> , 2013, 31, B216-B222.	1.7	79

#	ARTICLE	IF	CITATIONS
37	Progress Toward a Global Group A Streptococcal Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 180-182.	1.1	38
38	New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. <i>Vaccine</i> , 2011, 29, 8175-8178.	1.7	219
39	Streptococcal protective antigens (Spa): a new family of type-specific proteins of group A streptococci. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2010, 29, 51-57.	1.3	9
40	Prevalence of Rheumatic Heart Disease in Children and Young Adults in Nicaragua. <i>American Journal of Cardiology</i> , 2010, 105, 1809-1814.	0.7	165
41	The NH ₂ -terminal Region of <i>Streptococcus pyogenes</i> M5 Protein Confers Protection against Degradation by Proteases and Enhances Mucosal Colonization of Mice. <i>Journal of Infectious Diseases</i> , 2010, 201, 1580-1588.	1.9	6
42	Progress in the Development of Effective Vaccines to Prevent Selected Gram-Positive Bacterial Infections. <i>American Journal of the Medical Sciences</i> , 2010, 340, 218-225.	0.4	5
43	Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes. <i>Vaccine</i> , 2010, 28, 5017-5022.	1.7	36
44	Seven-Year Surveillance of North American Pediatric Group A Streptococcal Pharyngitis Isolates. <i>Clinical Infectious Diseases</i> , 2009, 49, 78-84.	2.9	97
45	Age-associated differences in prevalence of group A streptococcal type-specific M antibodies in children. <i>European Journal of Pediatrics</i> , 2009, 168, 679-683.	1.3	5
46	Relationship between Expression of the Family of M Proteins and Lipoteichoic Acid to Hydrophobicity and Biofilm Formation in <i>Streptococcus pyogenes</i> . <i>PLoS ONE</i> , 2009, 4, e4166.	1.1	88
47	Inactivation of DltA Modulates Virulence Factor Expression in <i>Streptococcus pyogenes</i> . <i>PLoS ONE</i> , 2009, 4, e5366.	1.1	39
48	Current Status of Group A Streptococcal Vaccine Development. <i>Advances in Experimental Medicine and Biology</i> , 2008, 609, 53-63.	0.8	46
49	The Importance of the Group A <i>Streptococcus</i> Capsule in the Pathogenesis of Human Infections: A Historical Perspective. <i>Clinical Infectious Diseases</i> , 2008, 46, 1038-1045.	2.9	75
50	Macrolide resistance among pediatric pharyngeal Group A streptococci is high in Canada and increasing in the US. <i>International Congress Series</i> , 2006, 1289, 95-98.	0.2	0
51	Five-year group A streptococcal pharyngitis serotype surveillance in North America, 2000-2005. <i>International Congress Series</i> , 2006, 1289, 30-33.	0.2	1
52	Role of the Mga regulon in the resistance of M type 4 <i>Streptococcus pyogenes</i> to phagocytosis. <i>International Congress Series</i> , 2006, 1289, 195-198.	0.2	0
53	Why acute rheumatic fever has virtually disappeared in the U.S.. <i>International Congress Series</i> , 2006, 1289, 285-288.	0.2	1
54	A double-blind, randomized phase II trial of the safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults. <i>International Congress Series</i> , 2006, 1289, 303-306.	0.2	19

#	ARTICLE	IF	CITATIONS
55	Anti-phagocytic mechanisms of Streptococcus pyogenes: binding of fibrinogen to M-related protein. <i>Molecular Microbiology</i> , 2006, 59, 936-947.	1.2	71
56	Temporal Changes in Streptococcal M Protein Types and the Near-Disappearance of Acute Rheumatic Fever in the United States. <i>Clinical Infectious Diseases</i> , 2006, 42, 441-447.	2.9	108
57	Prospects for a Group A Streptococcal Vaccine: Rationale, Feasibility, and Obstacles--Report of a National Institute of Allergy and Infectious Diseases Workshop. <i>Clinical Infectious Diseases</i> , 2005, 41, 1150-1156.	2.9	91
58	Multivalent Group A Streptococcal Vaccine Elicits Bactericidal Antibodies against Variant M Subtypes. <i>Vaccine Journal</i> , 2005, 12, 833-836.	3.2	48
59	Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers. <i>Clinical Infectious Diseases</i> , 2005, 41, 1114-1122.	2.9	271
60	Intranasal Immunization with Multivalent Group A Streptococcal Vaccines Protects Mice against Intranasal Challenge Infections. <i>Infection and Immunity</i> , 2004, 72, 2507-2512.	1.0	76
61	Group A Streptococcal Pharyngitis Serotype Surveillance in North America, 2000-2002. <i>Clinical Infectious Diseases</i> , 2004, 39, 325-332.	2.9	115
62	Progress in Group A Streptococcal Vaccine Development. <i>Pediatric Infectious Disease Journal</i> , 2004, 23, 765-766.	1.1	30
63	Safety and Immunogenicity of a Recombinant Multivalent Group A Streptococcal Vaccine in Healthy Adults. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 709.	3.8	144
64	Serum Opacity Factor (SOF) of Streptococcus pyogenes Evokes Antibodies That Opsonize Homologous and Heterologous SOF-Positive Serotypes of Group A Streptococci. <i>Infection and Immunity</i> , 2003, 71, 5097-5103.	1.0	56
65	Antibodies against a Synthetic Peptide of SagA Neutralize the Cytolytic Activity of Streptolysin S from Group A Streptococci. <i>Infection and Immunity</i> , 2002, 70, 2166-2170.	1.0	36
66	Southern Society for Clinical Investigation Founders' Medal Recipient's Address. <i>American Journal of the Medical Sciences</i> , 2002, 324, 61-62.	0.4	0
67	Immunogenicity of a 26-Valent Group A Streptococcal Vaccine. <i>Infection and Immunity</i> , 2002, 70, 2171-2177.	1.0	221
68	Molecular mechanisms of adhesion, colonization, and invasion of group A streptococci. <i>Annals of Medicine</i> , 2002, 34, 77-87.	1.5	150
69	Dynamic epidemiology of group A streptococcal serotypes. <i>Lancet, The</i> , 2002, 359, 889.	6.3	10
70	Mapping the Fibrinogen-Binding Domain of Serum Opacity Factor of Group A Streptococci. <i>Current Microbiology</i> , 2002, 44, 236-240.	1.0	29
71	Spa Contributes to the Virulence of Type 18 Group A Streptococci. <i>Infection and Immunity</i> , 2001, 69, 2943-2949.	1.0	29
72	Identification of a Gene within a Pathogenicity Island of Enterotoxigenic Escherichia coli H10407 Required for Maximal Secretion of the Heat-Labile Enterotoxin. <i>Infection and Immunity</i> , 2000, 68, 2766-2774.	1.0	77

#	ARTICLE	IF	CITATIONS
73	Serum opacity factor is a major fibronectin-binding protein and a virulence determinant of M type 2 Streptococcus pyogenes. <i>Molecular Microbiology</i> , 1999, 32, 89-98.	1.2	109
74	Comparison of adherence to and penetration of a human laryngeal epithelial cell line by group A streptococci of various M protein types. <i>FEMS Immunology and Medical Microbiology</i> , 1999, 23, 195-204.	2.7	23
75	Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments. <i>Vaccine</i> , 1999, 17, 193-200.	1.7	91
76	GROUP A STREPTOCOCCAL VACCINES. <i>Infectious Disease Clinics of North America</i> , 1999, 13, 227-243.	1.9	23
77	New protective antigen of group A streptococci. <i>Journal of Clinical Investigation</i> , 1999, 103, 1261-1268.	3.9	58
78	Opsonic Antibodies to the Surface M Protein of Group A Streptococci in Pooled Normal Immunoglobulins (IVIG): Potential Impact on the Clinical Efficacy of IVIG Therapy for Severe Invasive Group A Streptococcal Infections. <i>Infection and Immunity</i> , 1998, 66, 2279-2283.	1.0	51
79	Group A Streptococcal Vaccines. <i>Pediatric Annals</i> , 1998, 27, 301-308.	0.3	5
80	Conversion of M serotype 24 of Streptococcus pyogenes to M serotypes 5 and 18: effect on resistance to phagocytosis and adhesion to host cells. <i>Infection and Immunity</i> , 1997, 65, 2472-2474.	1.0	37
81	Recombinant, octavalent group A streptococcal M protein vaccine. <i>Vaccine</i> , 1996, 14, 944-948.	1.7	71
82	The Reemergence of Serious Group A Streptococcal Infections and Acute Rheumatic Fever. <i>American Journal of the Medical Sciences</i> , 1996, 311, 41-54.	0.4	42
83	The Reemergence of Serious Group A Streptococcal Infections and Acute Rheumatic Fever. <i>American Journal of the Medical Sciences</i> , 1996, 311, 41-54.	0.4	66
84	Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. <i>Infection and Immunity</i> , 1996, 64, 1495-1501.	1.0	159
85	Differential effects of the streptococcal fibronectin-binding protein, FBP54, on adhesion of group A streptococci to human buccal cells and HEP-2 tissue culture cells. <i>Infection and Immunity</i> , 1996, 64, 2415-2419.	1.0	104
86	Intranasal Immunization with Recombinant Group A Streptococcal M Protein Fragment Fused to the B Subunit of Escherichia coli Labile Toxin Protects Mice against Systemic Challenge Infections. <i>Journal of Infectious Diseases</i> , 1995, 171, 1038-1041.	1.9	45
87	Passive Protection of Mice against Group A Streptococcal Pharyngeal Infection by Lipoteichoic Acid. <i>Journal of Infectious Diseases</i> , 1994, 169, 319-323.	1.9	49
88	Analysis of the role of M24 protein in group A streptococcal adhesion and colonization by use of omega-interposon mutagenesis. <i>Infection and Immunity</i> , 1994, 62, 4868-4873.	1.0	63
89	Cloning, sequencing, and expression of a fibronectin/fibrinogen-binding protein from group A streptococci. <i>Infection and Immunity</i> , 1994, 62, 3937-3946.	1.0	152
90	Epitopes of streptococcal M proteins that evoke antibodies that cross-react with human brain. <i>Journal of Immunology</i> , 1993, 151, 2820-8.	0.4	133

#	ARTICLE	IF	CITATIONS
91	Recombinant tetravalent group A streptococcal M protein vaccine. <i>Journal of Immunology</i> , 1993, 151, 2188-94.	0.4	48
92	Lipoteichoic acid and M protein: dual adhesins of group A streptococci. <i>Microbial Pathogenesis</i> , 1992, 12, 199-208.	1.3	74
93	A 28-kilodalton fibronectin-binding protein of group a streptococci. <i>Current Microbiology</i> , 1992, 25, 245-250.	1.0	39
94	Streptococcal C5a peptidase is a highly specific endopeptidase. <i>Infection and Immunity</i> , 1992, 60, 5219-5223.	1.0	151
95	Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses. <i>Journal of Immunology</i> , 1992, 148, 888-93.	0.4	69
96	Epitopes of group A streptococcal M protein shared with antigens of articular cartilage and synovium. <i>Journal of Immunology</i> , 1991, 146, 3132-7.	0.4	50
97	Phosphorylase-cross-reactive antibodies evoked by streptococcal M protein. <i>Infection and Immunity</i> , 1990, 58, 774-778.	1.0	1
98	Human and murine antibodies cross-reactive with streptococcal M protein and myosin recognize the sequence GLN-LYS-SER-LYS-GLN in M protein. <i>Journal of Immunology</i> , 1989, 143, 2677-83.	0.4	128
99	Protective and autoimmune epitopes of streptococcal M proteins. <i>Vaccine</i> , 1988, 6, 192-196.	1.7	45
100	Comparison of the leader sequences of four group A streptococcal M protein genes. <i>Nucleic Acids Research</i> , 1988, 16, 4667-4677.	6.5	57
101	Protective and heart-crossreactive epitopes located within the NH2 terminus of type 19 streptococcal M protein.. <i>Journal of Experimental Medicine</i> , 1988, 167, 1849-1859.	4.2	51
102	Protective immunity evoked by locally administered group A streptococcal vaccines in mice. <i>Journal of Immunology</i> , 1988, 141, 2767-70.	0.4	24
103	Protective immunogenicity and T lymphocyte specificity of a trivalent hybrid peptide containing NH2-terminal sequences of types 5, 6, and 24 M proteins synthesized in tandem.. <i>Journal of Experimental Medicine</i> , 1987, 166, 647-656.	4.2	52
104	Human cytotoxic T lymphocytes evoked by group A streptococcal M proteins.. <i>Journal of Experimental Medicine</i> , 1987, 166, 1825-1835.	4.2	39
105	Monoclonal antibody to human renal glomeruli cross-reacts with streptococcal M protein. <i>Infection and Immunity</i> , 1987, 55, 2416-2419.	1.0	36
106	Sequence of protective epitopes of streptococcal M proteins shared with cardiac sarcolemmal membranes. <i>Journal of Immunology</i> , 1987, 139, 1285-90.	0.4	47
107	Sequence and type-specific immunogenicity of the amino-terminal region of type 1 streptococcal M protein. <i>Journal of Immunology</i> , 1987, 139, 3084-90.	0.4	33
108	Sequence of myosin-crossreactive epitopes of streptococcal M protein.. <i>Journal of Experimental Medicine</i> , 1986, 164, 1785-1790.	4.2	113

#	ARTICLE	IF	CITATIONS
109	Localization of protective epitopes of the amino terminus of type 5 streptococcal M protein.. Journal of Experimental Medicine, 1986, 163, 1191-1202.	4.2	76
110	Multiple, heart-cross-reactive epitopes of streptococcal M proteins.. Journal of Experimental Medicine, 1985, 161, 113-122.	4.2	161
111	Epitopes of streptococcal M proteins shared with cardiac myosin.. Journal of Experimental Medicine, 1985, 162, 583-591.	4.2	222
112	Structure-Function Analysis of Group A Streptococcal M Proteins with Hybridoma Antibodies. , 1985, , 1-21.		1
113	Expression of protective and cardiac tissue cross-reactive epitopes of type 5 streptococcal M protein in Escherichia coli. Infection and Immunity, 1985, 48, 198-203.	1.0	20
114	Common protective antigens of group A streptococcal M proteins masked by fibrinogen.. Journal of Experimental Medicine, 1984, 159, 1201-1212.	4.2	73
115	Unique and common protective epitopes among different serotypes of group A streptococcal M proteins defined with hybridoma antibodies. Infection and Immunity, 1984, 46, 267-269.	1.0	26
116	Type-specific immunogenicity of a chemically synthesized peptide fragment of type 5 streptococcal M protein.. Journal of Experimental Medicine, 1983, 158, 1727-1732.	4.2	73
117	Attachment of Streptococcus pyogenes to Mammalian Cells. Clinical Infectious Diseases, 1983, 5, S670-S677.	2.9	36
118	Repeating covalent structure and protective immunogenicity of native and synthetic polypeptide fragments of type 24 streptococcal M protein. Mapping of protective and nonprotective epitopes with monoclonal antibodies.. Journal of Biological Chemistry, 1983, 258, 13250-13257.	1.6	46
119	Repeating covalent structure and protective immunogenicity of native and synthetic polypeptide fragments of type 24 streptococcal M protein. Mapping of protective and nonprotective epitopes with monoclonal antibodies. Journal of Biological Chemistry, 1983, 258, 13250-7.	1.6	41
120	Protective antigenic determinant of streptococcal M protein shared with sarcolemmal membrane protein of human heart.. Journal of Experimental Medicine, 1982, 156, 1165-1176.	4.2	132
121	Hybridoma antibodies against protective and nonprotective antigenic determinants of a structurally defined polypeptide fragment of streptococcal M protein.. Journal of Experimental Medicine, 1982, 155, 1010-1018.	4.2	47
122	Type-specific antibodies to structurally defined fragments of streptococcal M proteins in patients with acute rheumatic fever. Infection and Immunity, 1982, 38, 573-579.	1.0	22
123	Protective antibody against a peptide fragment of type 5 streptococcal M protein cross-reacts with human heart tissue. Transactions of the Association of American Physicians, 1982, 95, 286-91.	0.1	5
124	Type-specific protective immunity evoked by synthetic peptide of Streptococcus pyogenes M protein. Nature, 1981, 292, 457-459.	13.7	194
125	Blastogenic responses of human lymphocytes to structurally defined polypeptide fragments of streptococcal M protein. Journal of Immunology, 1981, 126, 1499-505.	0.4	36
126	Heterogeneity of type-specific and cross-reactive antigenic determinants within a single M protein of group A streptococci.. Journal of Experimental Medicine, 1980, 151, 1026-1038.	4.2	43